U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07733947) titled 'A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)' on July 24.
Brief Summary: A Phase 3b, Multicenter, Two stage, Double-blind, Long term Follow up and Open-label Extension Study of Participants Who have Completed the CBL-0301 or CBL-0302 Study for Reducing Abdominal Subcutaneous Fat (Stage 1)
Study Start Date: Dec., 2026
Study Type: INTERVENTIONAL
Condition:
Subcutaneous Fat
Intervention:
DRUG: CBL-514 Injection
Provided as a ready for use injectable CBL-514 solution
DRUG: 0.9 % sodium chloride
Injectable 0.9% Sodium Chloride solution as placeb...